Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 29Esophageal Neoplasms 18Squamous Cell Carcinoma of Head and Neck 15Carcinoma, Non-Small-Cell Lung 14Nasopharyngeal Carcinoma 12Uterine Cervical Neoplasms 11Head and Neck Neoplasms 11Pancreatic Neoplasms 8Oropharyngeal Neoplasms 8Lung Neoplasms 6Glioblastoma 6Carcinoma, Squamous Cell 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Mouth Neoplasms 4Hypopharyngeal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Colorectal Neoplasms 4Adenocarcinoma 4Radiation Injuries 3Pathologic Complete Response 3Carcinoma 3Breast Neoplasms 3Thymoma 2Resectable Esophageal Cancer 2Neoplasms 2Nasopharyngeal Neoplasms 2NSCLC 2Lymphoma 2Lymphatic Metastasis 2

Interventions

tremelimumab 1durvalumab 1Specimen Handling 1Radiosurgery 1Medical Marijuana 1Heavy Ion Radiotherapy 1Gemcitabine 1Chemoradiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pancreatic Cancer Non-resectable × Chemoradiotherapy × Clear all
NCT07386704 2026-02-04

Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer

Peking University First Hospital

Phase 2 Enrolling by invitation
30 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡